Publications by authors named "J F Forteza Alberti"
Human activities alter biomass, nutrient availability, and species dominance in grasslands, impacting their richness, composition, and biomass production. Stability (invariability in time or space) can inform the predictability of plant communities in response to human activities. However, this measure has been simplistically analyzed for temporal (interannual) changes in live biomass, disregarding their spatial stability and the temporal stability of other plant community attributes.
View Article and Find Full Text PDFArticle Synopsis
- * Sites with warmer, wetter conditions and more species generally saw increased biomass, while arid, species-poor areas experienced declines, alongside notable changes in seasonal plant growth patterns.
- * Factors like grazing and nutrient input didn't consistently predict biomass changes, indicating that grasslands are undergoing substantial transformations that could affect food security, biodiversity, and carbon storage, particularly in dry regions.
The tourism industry, affected by COVID-19, must reduce greenhouse gas emissions. This study evaluated the environmental impact of three hotels in coastal and mountainous regions of Spain and Portugal using Life Cycle Assessment (LCA). Data was gathered via surveys in the Greentour tool.
View Article and Find Full Text PDFPurpose: Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting.
Methods: The randomized multicenter phase II PACE trial enrolled patients with hormone receptor-positive/HER2- MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy. Patients were randomly assigned 1:2:1 to receive fulvestrant (F), fulvestrant plus palbociclib (F + P), or fulvestrant plus palbociclib and avelumab (F + P + A).